Does splenectomy significantly improve the prognosis of hepatocellular carcinoma patients with hypersplenism? A systematic review and meta-analysis

被引:10
作者
Shi, Xue-Bing [1 ]
Feng, Jin-Kai [2 ]
Wang, Jing-Han [1 ]
Jiang, Xiao-Qing [1 ]
机构
[1] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Biliary Tract Surg 1, 225 Changhai Rd, Shanghai 200433, Peoples R China
[2] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma (HCC); hypersplenism; hepatectomy; splenectomy; prognosis; PORTAL-VEIN THROMBOSIS; LIVER-CIRRHOSIS; RESECTION;
D O I
10.21037/atm-20-6748
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Whether hepatocellular carcinoma (HCC) patients with hypersplenism can benefit from splenectomy is unclear. This study aimed at exploring the efficacy and safety of concurrent splenectomy for HCC patients with hypersplenism. Methods: PubMed, EMBASE and Web of Science databases were systematically searched to compare data on the combination of hepatectomy or transhepatic arterial infusion (TAI) with splenectomy (the splenectomy group) with data on hepatectomy or TAI alone (the non-splenectomy group) for the treatment of HCC with hypersplenism. Prospective clinical trials or retrospective cohort studies from inception to May 10, 2020 were considered eligible for this analysis. The relevant outcomes, including patients' demographics, clinicopathologic characteristics, perioperative indices and long-term outcomes, were independently extracted by two investigators. Publication bias for overall survival (OS) and disease-free survival (DFS) was qualitatively assessed by funnel plots and quantitatively evaluated by Begg's and Egger's tests. Results: Nine retrospective studies including 1,650 patients were analyzed. Short-term outcomes suggested that the incidence rate of postoperative complications, including portal or splenic vein thrombosis [odds ratio (OR) = 26.28, P<0.001] and pancreatic injury (OR = 14.89, P=0.001), was significantly higher in the splenectomy group, whereas the perioperative mortality rate was similar between the splenectomy and non-splenectomy groups (P=0.541). Long-term outcomes indicated that the occurrence of variceal rehemorrhage (OR = 0.31, P<0.001) and tumor progress or recurrence (OR = 0.62, P=0.001) was markedly reduced for patients who underwent splenectomy, while the long-term mortality rates were not statistically different between the two groups (P=0.087). The prognostic evaluation revealed that the OS and DFS were comparable between the splenectomy and non-splenectomy groups [for OS: hazard ratio (HR) = 0.77, 95% confidence interval (CI): 0.53-1.13; for DFS: HR = 0.87, 95% CI: 0.63-1.19]. Funnel plots suggested an HRs symmetric distribution for OS and DFS. Begg's and Egger's tests confirmed that there was no significant HR publication bias for OS and DFS. Conclusions: Due to the significant progress in surgical techniques and perioperative care, concomitant splenectomy should be considered as an optional treatment for some HCC patients with hypersplenism.
引用
收藏
页数:15
相关论文
共 36 条
  • [1] Warfarin versus aspirin prevents portal vein thrombosis after laparoscopic splenectomy and azygoportal disconnection: A randomized clinical trial
    Bai, Dou-Sheng
    Xia, Bing-Lan
    Zhang, Chi
    Ye, Jing
    Qian, Jian-Jun
    Jin, Sheng-Jie
    Jiang, Guo-Qing
    [J]. INTERNATIONAL JOURNAL OF SURGERY, 2019, 64 : 16 - 23
  • [2] Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism
    Chen, XP
    Wu, ZD
    Huang, ZY
    Qiu, FZ
    [J]. BRITISH JOURNAL OF SURGERY, 2005, 92 (03) : 334 - 339
  • [3] European Assoc Study Liver, 2018, J HEPATOL, V69, P154, DOI 10.1016/j.jhep.2018.03.018
  • [4] Hepatocellular carcinoma
    Forner, Alejandro
    Llovet, Josep M.
    Bruix, Jordi
    [J]. LANCET, 2012, 379 (9822) : 1245 - 1255
  • [5] AASLD guidelines for the treatment of hepatocellular carcinoma
    Heimbach, Julie K.
    Kulik, Laura M.
    Finn, Richard S.
    Sirlin, Claude B.
    Abecassis, Michael M.
    Roberts, Lewis R.
    Zhu, Andrew X.
    Murad, M. Hassan
    Marrero, Jorge A.
    [J]. HEPATOLOGY, 2018, 67 (01) : 358 - 380
  • [6] Measuring inconsistency in meta-analyses
    Higgins, JPT
    Thompson, SG
    Deeks, JJ
    Altman, DG
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7414): : 557 - 560
  • [7] The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
    Higgins, Julian P. T.
    Altman, Douglas G.
    Gotzsche, Peter C.
    Jueni, Peter
    Moher, David
    Oxman, Andrew D.
    Savovic, Jelena
    Schulz, Kenneth F.
    Weeks, Laura
    Sterne, Jonathan A. C.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
  • [8] Efficacy of splenectomy for hypersplenic patients with advanced hepatocellular carcinoma
    Hirooka, Masashi
    Ishida, Kiyotaka
    Kisaka, Yoshiyasu
    Uehara, Takahide
    Watanabe, Yuji
    Hiasa, Yoichi
    Michitaka, Kojiro
    Onji, Morikazu
    [J]. HEPATOLOGY RESEARCH, 2008, 38 (12) : 1172 - 1177
  • [9] Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma
    Ishizawa, Takeaki
    Hasegawa, Kiyoshi
    Aoki, Taku
    Takahashi, Michiro
    Inoue, Yosuke
    Sano, Keiji
    Imamura, Hiroshi
    Sugawara, Yasuhiko
    Kokudo, Norihiro
    Makuuchi, Masatoshi
    [J]. GASTROENTEROLOGY, 2008, 134 (07) : 1908 - 1916
  • [10] Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.21492, 10.3322/caac.20115, 10.3322/caac.20107]